SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Takeda Pharmaceutical Company Limited (TAK) News

Follow Takeda Pharmaceutical Company Limited (TAK) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol TAK Asset equity Sector Markets 90 days 5 Last 21.43 Updated Oct 29, 2026, 07:52 AM UTC Open live news feed Open TAK chart & news
M Takeda Reports Higher H1 Core Earnings and Revenue, Lifts 2026 Guidance Takeda Pharmaceutical reported higher first-half core earnings and revenue and lifted its 2026 guidance. EARNINGS | Oct 29, 2026, 07:52 AM UTC M Takeda Reports Positive Phase 3 Results for Arcotatug Tavatecan Takeda said the G-HOPE-001 study showed statistically significant and clinically meaningful improvements in overall survival and progression-free survival in previously treated advanced gastric or gastroesophageal juncti EQUITY | Oct 23, 2026, 11:30 AM UTC L Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill Takeda (TSE:4502/NYSE:TAK) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibit NEWS | Sep 30, 2026, 05:00 AM UTC H Full Transcript: Takeda Pharmaceutical Co Q1 2026 Earnings Call Takeda Pharmaceutical Co (NYSE: TAK ) released first-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you APIs. For real-time access to LIVE | Sep 17, 2026, 01:06 PM UTC M Takeda's Orzeyful gets Japan approval for narcolepsy type 1 Takeda Pharmaceutical's Orzeyful (oveporexton) is approved in Japan as the first and only medicine to treat the underlying cause of narcolepsy type 1, marking its third major regulatory approval worldwide. REGULATION | Aug 24, 2026, 10:38 AM UTC L CORRECTION: Takeda Pharmaceutical Co Affirms FY2026 Adj EPS Guidance of $3.01 vs $1.57 Est; Affirms FY2026 Sales Guidance of $29.585B vs $28 Takeda Pharmaceutical Co (NYSE: TAK ) affirms FY2026 Adj EPS guidance from $3.01 to $3.01 vs $1.57 analyst estimate. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion vs $28.950 billion estimate. EARNINGS | Jul 30, 2026, 12:12 PM UTC L Takeda Pharmaceutical Co Lowers FY2026 Adj EPS Guidance from $3.01 to $2.96 vs $1.57 Est; Lowers FY2026 Sales Guidance from $29.585B to $29. Takeda Pharmaceutical Co (NYSE: TAK ) lowers FY2026 Adj EPS guidance from $3.01 to $2.96 vs $1.57 analyst estimate. Lowers FY2026 sales outlook from $29.585 billion to $29.116 billion vs $28.950 billion estimate. EARNINGS | Jul 30, 2026, 07:44 AM UTC L Takeda Makes Fresh AI Drug Discovery Bet With Insilico Medicine Insilico Medicine said Thursday it entered into a strategic collaboration with Takeda Pharmaceutical Co. Ltd. (NYSE: TAK ) to use its proprietary Pharma.AI platform to discover and advance new drug candidates across mult EQUITY | Jul 02, 2026, 05:38 PM UTC L Takeda Pharmaceutical shares are trading higher after the company announced a $600 million AI drug discovery partnership with Insilico Medic Takeda Pharmaceutical shares are trading higher after the company announced a $600 million AI drug discovery partnership with Insilico Medicine. EQUITY | Jul 02, 2026, 02:02 PM UTC L Insilico Medicine Announced Earlier, AI Drug Discovery Collaboration With Takeda Worth Up To $600M; Insilico To Receive~$60M In Initiation F Insilico Medicine Announced Earlier, AI Drug Discovery Collaboration With Takeda Worth Up To $600M; Insilico To Receive~$60M In Initiation Fees, Near-Term Payments, Milestones, Eligible For Additional Preclinical, Clinic EQUITY | Jul 02, 2026, 09:15 AM UTC M TAK: Takeda Leans Into AI Takeda's first female CEO is utilizing AI to shape the biopharma business. EQUITY | Jun 26, 2026, 03:46 PM UTC M Takeda Names Julie Kim CEO Takeda appoints Julie Kim as Representative Director, President, and CEO as Christophe Weber retires EQUITY | Jun 24, 2026, 07:48 AM UTC